comparemela.com

Latest Breaking News On - சத்தீஷ் கண்ணன் - Page 4 : comparemela.com

MediBuddy new brand tagline is 'Your Health Buddy'

MediBuddy new brand tagline is ‘Your Health Buddy’ The new tagline not only aligns the brand with a more gender-neutral approach, citing equality in nature but also the importance of healthcare for every individual regardless of gender. The logo has also been revamped with a more vibrant look Delhi, March 02, 2021 Digital healthcare platform MediBuddy has revealed its revamped corporate identity with the brand’s new tagline and a more vibrant logo. Going forward, the brand will transition to a new tagline from “Aapka Health Buddy” to “Your Health Buddy”. The new tagline not only aligns the brand with a more gender-neutral approach, citing equality in nature but also the importance of healthcare for every individual regardless of gender.

India
Ashish-bajaj
Satish-kannan
Your-health-buddy
Bestmediainfo-bureau
Aapka-health-buddy-to-your
Bestmediainfo-bureau-delhi
Health-buddy
Mediainfo-bureau-delhi
Medibuddy
இந்தியா
ஆஷிஷ்-பஜாஜ்

MediBuddy raises $20mn funding from India Life Sciences Fund III, others

Health-tech company MediBuddy on Monday said it raised USD 20 million (about Rs 145 crore) earlier this month from India Life Sciences Fund III, LLC and others. The company had announced an initial funding of USD 20 million in June last year under the series B round, a statement said. The additional infusion of USD 20 million led by India Life Sciences Fund III, LLC, with participation from other investors, it added. The series B round has attracted new investments from India Life Sciences Fund III, LLC, TEAMFund LP, JAFCO Asia Fund, FinSight Ventures, ALES Global Japan and Beyond Next Ventures. The round has also seen participation from existing investors including Bessemer Venture Partners, Milliways Ventures and Rebright Partners. The company has raised over USD 50 million so far.

Japan
India
Satish-kannan
Asia-fund
India-life-sciences-fund
Finsight-ventures
Beyond-next
Bessemer-venture-partners
Milliways-ventures
Innoven-capital
Startups
Startups-latest-news

MediBuddy raises Rs 25 crore debt fund from InnoVen Capital

Digital healthcare platform MediBuddy has raised Rs 25 crore debt fund from InnoVen Capital, the venture debt firm said on Tuesday. MediBuddy recently closed around Rs 290 crore Series B round which was led by India Life Sciences Fund III, LLC. We have been an active investor in the Healthcare space and believe that tech first, AI-driven platforms like MediBuddy are well-positioned to disrupt the market, and we are delighted to back them in their vision to make quality healthcare accessible for all, InnoVen Capital India Chief Executive Officer (CEO) Ashish Sharma said in a statement. MediBuddy claims to have a network of over 90,000 doctors, 7,000 hospitals, 3,000 diagnostic centres and 2,500 pharmacies, covering over 95 per cent of all PIN codes.

India
Satish-kannan
Ashish-sharma
India-life-sciences-fund
Innoven-capital
Ven-capital-india-chief-executive-officer
Healthcare-sector
Fundraising
Medibuddy-raises-rs-25-crore-debt-fund-from-innoven-capital
இந்தியா
சத்தீஷ்-கண்ணன்
ஆஷிஷ்-ஷர்மா

MediBuddy wraps up $40M Series B Round

MediBuddy wraps up $40M Series B Round MediBuddy wraps up $40M Series B Round 02 February 2021 | News The Series B round attracted new investments from India Life Sciences Fund III, LLC, TEAMFund LP, JAFCO Asia Fund, FinSight Ventures, ALES Global Japan and Beyond Next Ventures Source credit: Shutterstock Bengaluru based startup MediBuddy has announced the closure of its $40 Million Series B Round. This follows the recent infusion of $20 million led by India Life Sciences Fund III, LLC, with participation from other investors. The digital healthcare platform had earlier announced an initial funding of $20 million (Rs 150 crore) in June 2020 under this round.

Japan
India
Satish-kannan
Yousuf-mazhar
Vikul-goyal
Asia-fund
India-life-sciences-fund
Finsight-ventures
Beyond-next
Bessemer-venture-partners
Milliways-ventures
Rebright-partners

vimarsana © 2020. All Rights Reserved.